ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Eighteen-month real-world outcomes of intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration: a UK single-centre experience.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIntravitreal aflibercept 8 mg was developed to extend treatment intervals and reduce injection burden in neovascular age-related macular degeneration (nAMD). We evaluated visual, anatomical, and durability outcomes over 18 months in routine clinical practice.
methodsThis retrospective observational study included 102 eyes of 95 treatment-naïve nAMD patients commencing aflibercept 8 mg at a UK tertiary centre. All eyes received three loading injections followed by a treat-and-extend protocol. Best-recorded visual acuity (BRVA), central subfield thickness (CST), intraretinal fluid (IRF), subretinal fluid (SRF), and macular haemorrhage were assessed at baseline, post-loading, 12 months, and 18 months. Linear and generalised mixed-effects models were applied.
resultsMean patient age was 81.1 ± 6.5 years; 68.4% were female. Mean BRVA was 62.5 ± 12.4 letters at baseline, 67.5 ± 13.7 post-loading, 66.8 ± 15.3 at 12 months (n = 102), and 65.5 ± 18.5 letters at 18 months (n = 73). Mean CST was 317.1 ± 95.4 μm at baseline, 237.9 ± 45.2 μm post-loading, 236.3 ± 51.7 μm at 12 months, and 220.6 ± 32.2 μm at 18 months (n = 73). At 12 months, 51.9% of eyes achieved treatment intervals of ≥ 12 weeks, increasing to 73.9% at 18 months. No cases of endophthalmitis were recorded.
conclusionAflibercept 8 mg achieved sustained visual acuity, significant anatomical improvement, and progressively extended treatment intervals over 18 months in treatment-naïve nAMD within routine clinical practice, supporting its effectiveness in reducing treatment burden without compromising disease control.
Indexed as
Identifiers
42814127What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.